News
Public · Published
Barclays maintains Inspire Medical Systems at Underweight, lowers price target to $62 from $65
Barclays kept an Underweight rating on Inspire Medical Systems and cut its price target to $62 from $65, a 4.6% decrease. The new target implies a 7.8% fall from the November 2 close of $67.21. Underweight means the analyst expects the stock to lag the market.
Published:
Updated:
What happened
Barclays kept an Underweight rating on Inspire Medical Systems and cut its price target to $62 from $65, a 4.6% decrease. The new target implies a 7.8% fall from the November 2 close of $67.21. Underweight means the analyst expects the stock to lag the market.
Confirmed
Global impact / market context
A lower price target signals the analyst expects less upside or more downside for Inspire shares, which can prompt some investors to sell or avoid the stock. It also affects how the company is viewed when raising money or negotiating with partners.
Analyst inference
Analyst targets on Inspire currently range from $65 to $78 across recent notes, so Barclays now sits at the low end after cutting its own view. That gap shows divided opinions, which can make the stock trade more sharply around news.
Analyst inference
What to watch
- Watch whether other analysts also lower their price targets or ratings on Inspire Medical Systems after Barclays, since targets now range from $65 to $78. Confirmed
- Watch for future Barclays updates, such as raising or further cutting the $62 target, to see whether its cautious Underweight view becomes more or less severe. Proposed
- Track Inspire's sales growth and spending plans for signs of whether the analyst's downside expectation is playing out in the business results. Analyst inference
Evidence
- Original source link unavailable